Comprehensive Evaluation of IgG, IgM, and Total Antioxidant Capacity in Breast Cancer Patients in Kirkuk: Insights into Immune and Oxidative Stress Markers

Suzan Aladdin Younis; Sayran Sattar  Saleh

doi:10.17605/cajmns.v6i4.2895

Suzan Aladdin Younis Department of Chemistry, College of Science, University of Kirkuk, Kirkuk, Iraq
Sayran Sattar Saleh Department of Chemistry, College of Science, University of Kirkuk, Kirkuk, Iraq

DOI: https://doi.org/10.17605/cajmns.v6i4.2895

Keywords: Breast Cancer, Immunoglobulin G (IgG), Immunoglobulin M (IgM), Total Antioxidant Capacity (TAC)

Abstract

Breast cancer remains the most frequently diagnosed life-threatening malignancy in women and continues to be the leading cause of cancer-related mortality in this population. Globally, it is the second most common cause of cancer-related deaths among women. In Iraq, breast cancer represents the most prevalent form of malignancy among females, accounting for approximately one-third of all documented female cancer cases, according to the most recent data from the Iraqi Cancer Registry ,This study was conducted on a cohort of breast cancer patients and healthy volunteers from Kirkuk Governorate in northern Iraq. A total of 95 participants were enrolled, comprising 50 breast cancer patients and 45 age-matched healthy controls , The primary objective of this study was to assess the circulating levels of Immunoglobulin G (IgG), Immunoglobulin M (IgM), and Total Antioxidant Capacity (TAC) in breast cancer patients and to explore their potential utility as diagnostic or prognostic biomarkers , The findings demonstrated significantly elevated concentrations of IgG and IgM, along with a marked reduction in TAC levels among breast cancer patients when compared to the control group (p < 0.05). These results highlight the critical involvement of immune dysregulation and oxidative stress in the pathophysiology and progression of breast cancer.

References

G. N. Sharma, R. Dave, J. Sanadya, P. Sharma, and K. Sharma, “Various types and management of breast cancer: an overview,” J. Adv. Pharm. Technol. Res., vol. 1, no. 2, pp. 109–126, Apr. 2010.

M. M. Al-Hashimi, “Trends in breast cancer incidence in Iraq during the period 2000–2019,” Asian Pac. J. Cancer Prev., vol. 22, no. 12, pp. 3889–3894, Dec. 2021.

F. Karar, I. G. Zainal, and M. O. Mohammed, “Effects of ascorbic and cinnamic acids on the albumin glycation level in breast cancer patients,” Cancer, vol. 16, no. 17, pp. 18–19, 2009.

Z. S. AL-Garawi and I. G. Zainal, “Study of total protein and protein profile in patients with (breast, ovary and uterus) cancer,” Diyala J. Human Res., no. 39, 2009.

S. N. Jasim, A. M. Ahmed, and S. S. Saleh, “Estimation of trace elements (selenium, iron) and their biological effect in serum levels of breast cancer patients,” Med. J. Babylon, vol. 17, no. 1, pp. 89–92, Jan. 2020.

Y. A. Anwer Sultan and S. S. Saleh, “Study of the effect of chemotherapy on some serum antioxidants and partly purified glutathione peroxidase from patients with breast cancer,” Int. J. Sci. Basic Appl. Res., vol. 43, no. 1, pp. 30–34, Jan. 2019.

H. T. Hashim, M. A. Ramadhan, K. M. Theban, J. Bchara, A. El-Abed-El-Rassoul, and J. Shah, “Assessment of breast cancer risk among Iraqi women in 2019,” BMC Women’s Health, vol. 21, no. 1, pp. 1–9, Dec. 2021.

G. D. Jacobsen and K. H. Jacobsen, “Health awareness campaigns and diagnosis rates: evidence from National Breast Cancer Awareness Month,” J. Health Econ., vol. 30, no. 1, pp. 55–61, Jan. 2011.

S. Zhang et al., “Immune profile differences in breast cancer patients with and without BRCA mutations,” J. Immunol., vol. 202, no. 3, pp. 678–687, 2019.

H. Sies and D. P. Jones, “Reactive oxygen species (ROS) as pleiotropic physiological signalling agents,” Nat. Rev. Mol. Cell Biol., vol. 21, no. 7, pp. 363–383, 2020.

M. Valko, D. Leibfritz, J. Moncol, et al., “Free radicals and antioxidants in normal physiological functions and human disease,” Int. J. Biochem. Cell Biol., vol. 39, no. 1, pp. 44–84, 2007.

M. Schmidt, B. Hellwig, S. Hammad, et al., “A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors,” Clin. Cancer Res., vol. 18, no. 9, pp. 2695–2703, 2012.

F. Nimmerjahn and J. V. Ravetch, “Fcγ receptors as regulators of immune responses,” Nat. Rev. Immunol., vol. 8, no. 1, pp. 34–47, 2008.

W. Zou, “Immunosuppressive networks in the tumour environment and their therapeutic relevance,” Nat. Rev. Cancer, vol. 5, no. 4, pp. 263–274, Apr. 2005.

C. Wersal, A. Keller, C. Weiss, F. A. Giordano, Y. Abo-Madyan, B. Tuschy, M. Sütterlin, F. Wenz, and E. Sperk, “Long-term changes in blood counts after intraoperative radiotherapy for breast cancer—single center experience and review of the literature,” Transl. Cancer Res., vol. 8, no. 5, pp. 1882–1892, Sep. 2019.

C. Li, X. Yu, X. Han, C. Lian, Z. Wang, S. Shao, F. Shao, H. Wang, S. Ma, and J. Liu, “Innate immune cells in tumour microenvironment: a new frontier in cancer immunotherapy,” iScience, Aug. 2024.

P. B. Olkhanud, B. Damdinsuren, M. Bodogai, R. E. Gress, R. Sen, K. Wejksza, E. Malchinkhuu, R. P. Wersto, and A. Biragyn, “Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4+ T cells to T-regulatory cells,” Cancer Res., vol. 71, no. 10, pp. 3505–3515, May 2011.

M. Cui, J. Huang, S. Zhang, Q. Liu, Q. Liao, and X. Qiu, “Immunoglobulin expression in cancer cells and its critical roles in tumorigenesis,” Front. Immunol., vol. 12, 613530, Mar. 2021.

A. K. Mehta, S. Kadel, M. G. Townsend, M. Oliwa, and J. L. Guerriero, “Macrophage biology and mechanisms of immune suppression in breast cancer,” Front. Immunol., vol. 12, 643771, Apr. 2021.

S. Reuter, S. C. Gupta, M. M. Chaturvedi, and B. B. Aggarwal, “Oxidative stress, inflammation, and cancer: how are they linked?,” Free Radic. Biol. Med., vol. 49, no. 11, pp. 1603–1616, Dec. 2010.

L. J. Miller, C. Douglas, F. S. McCullough, S. J. Stanworth, and P. C. Calder, “Impact of enteral immunonutrition on infectious complications and immune and inflammatory markers in cancer patients undergoing chemotherapy: A systematic review of randomised controlled trials,” Clin. Nutr., vol. 41, no. 10, pp. 2135–2146, Oct. 2022.

A. Razzaghdoust, B. Mofid, and M. Zangeneh, “Predicting chemotherapy-induced thrombocytopenia in cancer patients with solid tumors or lymphoma,” J. Oncol. Pharm. Pract., vol. 26, no. 3, pp. 587–594, Apr. 2020.

D. R. Germolec, K. A. Shipkowski, R. P. Frawley, and E. Evans, “Markers of inflammation,” in Immunotoxicity Testing: Methods and Protocols, 2018, pp. 57–79.

J. Kruk and H. Y. Aboul-Enein, “Reactive oxygen and nitrogen species in carcinogenesis: implications of oxidative stress on the progression and development of several cancer types,” Mini Rev. Med. Chem., vol. 17, no. 11, pp. 904–919, 2017.

V. Sosa, T. Moliné, R. Somoza, et al., “Oxidative stress and cancer: an overview,” Ageing Res. Rev., vol. 12, no. 1, pp. 376–390, 2013.

D. Trachootham, J. Alexandre, and P. Huang, “Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?,” Nat. Rev. Drug Discov., vol. 8, no. 7, pp. 579–591, 2009.

M. L. Disis, “Immune regulation of cancer,” J. Clin. Oncol., vol. 28, no. 29, pp. 4531–4538, 2010.

A. L. Palacios-Acedo, M. Langiu, L. Crescence, D. Mège, C. Dubois, L. Panicot-Dubois, “Platelet and cancer-cell interactions modulate cancer-associated thrombosis risk in different cancer types,” Cancers, vol. 14, no. 3, p. 730, Jan. 2022.

L. Chen, X. Kong, C. Yan, Y. Fang, and J. Wang, “The research progress on the prognostic value of the common hematological parameters in peripheral venous blood in breast cancer,” OncoTargets Ther., pp. 1397–1412, Feb. 2020.

A. Jones, J. Smith, and L. Brown, “Platelet counts and their clinical significance in cancer patients,” Cancer Res. Treat., vol. 21, no. 2, pp. 123–134, 2019.

A. Razzaghdoust, B. Mofid, and M. Zangeneh, “Predicting chemotherapy-induced thrombocytopenia in cancer patients with solid tumors or lymphoma,” J. Oncol. Pharm. Pract., vol. 26, no. 3, pp. 587–594, Apr. 2020.

G. M. Rodgers, P. S. Becker, M. Blinder, D. Cella, A. Chanan-Khan, C. Cleeland, P. F. Coccia, B. Djulbegovic, J. A. Gilreath, E. H. Kraut, U. A. Matulonis, “Cancer-and chemotherapy-induced anemia,” J. Natl. Compr. Cancer Netw., vol. 10, no. 5, pp. 628–653, May 2012.

M. Wiciński, G. Liczner, K. Cadelski, T. Kołnierzak, M. Nowaczewska, and B. Malinowski, “Anemia of chronic diseases: wider diagnostics—better treatment?,” Nutrients, vol. 12, no. 6, p. 1784, Jun. 2020.

R. A. Castillo-Rodríguez, C. Trejo-Solís, A. Cabrera-Cano, S. Gómez-Manzo, and V. M. Dávila-Borja, “Hypoxia as a modulator of inflammation and immune response in cancer,” Cancers, vol. 14, no. 9, p. 2291, May 2022.

J. Varlotto and M. A. Stevenson, “Anemia, tumor hypoxemia, and the cancer patient,” Int. J. Radiat. Oncol. Biol. Phys., vol. 63, no. 1, pp. 25–36, Sep. 2005.

D. G. DeNardo and L. M. Coussens, “Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression,” Breast Cancer Res., vol. 9, no. 4, p. 212, Aug. 2007.

M. Dougan and G. Dranoff, “Immune therapy for cancer,” Annu. Rev. Immunol., vol. 27, no. 1, pp. 83–117, Apr. 2009.

P. Madki, M. L. Tejasvi, G. Paramkusam, and R. Khan, “Evaluation of serum immunoglobulins (IgG, IgA, IgM) and circulating immune complexes in oral precancer and cancer patients,” Glob. Med. Genet., vol. 8, no. 3, pp. 95–99, Sep. 2021.

J. Y. Yeon, Y. J. Suh, S. W. Kim, H. W. Baik, C. J. Sung, H. S. Kim, and M. K. Sung, “Evaluation of dietary factors in relation to the biomarkers of oxidative stress and inflammation in breast cancer risk,” Nutrition, vol. 27, no. 9, pp. 912–918, Sep. 2011.

A. T. Babakr and M. M. Eldein, “Assessment of lipid peroxidation and total antioxidant capacity in patients with breast cancer,” Explor. Target. Anti-tumor Ther., vol. 6, p. 1002284, Jan. 2025.

S. Demirci-Çekiç, G. Özkan, A. N. Avan, S. Uzunboy, E. Çapanoğlu, and R. Apak, “Biomarkers of oxidative stress and antioxidant defense,” J. Pharm. Biomed. Anal., vol. 209, p. 114477, Feb. 2022.

T. W. LeBien and T. F. Tedder, “B lymphocytes: how they develop and function,” Blood, vol. 112, no. 5, pp. 1570–1580, Sep. 2008.

D. Frasca and B. B. Blomberg, “Aging affects human B cell responses,” J. Clin. Immunol., vol. 31, pp. 430–435, Jun. 2011.

A. Panda, A. Arjona, E. Sapey, F. Bai, E. Fikrig, R. R. Montgomery, J. M. Lord, and A. C. Shaw, “Human innate immunosenescence: causes and consequences for immunity in old age,” Trends Immunol., vol. 30, no. 7, pp. 325–333, Jul. 2009.

N. Engels and J. Wienands, “Memory control by the B cell antigen receptor,” Immunol. Rev., vol. 283, no. 1, pp. 150–160, May 2018.

D. Trachootham, J. Alexandre, and P. Huang, “Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?,” Nat. Rev. Drug Discov., vol. 8, no. 7, pp. 579–591, Jul. 2009.

C. López-Otín, M. A. Blasco, L. Partridge, M. Serrano, and G. Kroemer, “The hallmarks of aging,” Cell, vol. 153, no. 6, pp. 1194–1217, Jun. 2013.

T. Finkel and N. J. Holbrook, “Oxidants, oxidative stress and the biology of ageing,” Nature, vol. 408, no. 6809, pp. 239–247, Nov. 2000.

J. Gumulec, M. Masarik, S. Krizkova, V. Adam, J. Hubalek, J. Hrabeta, et al., “Insight to physiology and pathology of zinc(II) ions and their actions in breast and prostate carcinoma,” Curr. Med. Chem., vol. 21, no. 5, pp. 564–579, 2014.